Comprehensive evaluation of the child with intellectual disability or global developmental delays

Pediatrics

Volumn 134, Issue 3, 2014, Pages e903-e918

  Moeschler, John B ^a   Shevell, Michael ^a   Saul, Robert A ^a   Chen, Emily ^a   Freedenberg, Debra L ^a   Hamid, Rizwan ^a   Jones, Marilyn C ^a   Stoler, Joan M ^a   Tarini, Beth Anne ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

METHYL CPG BINDING PROTEIN 2;

ARTICLE; CHILD; CHROMOSOME ANALYSIS; CHROMOSOME MICROARRAY; CHROMOSOME REARRANGEMENT; COMPARATIVE GENOMIC HYBRIDIZATION; COMPUTER ASSISTED TOMOGRAPHY; COPY NUMBER VARIATION; DEVELOPMENTAL DISORDER; DIAGNOSTIC VALUE; EXOME; FLUORESCENCE IN SITU HYBRIDIZATION; FRAGILE X SYNDROME; GENETIC SCREENING; GLOBAL DEVELOPMENTAL DELAY; HOME CARE; HUMAN; INBORN ERROR OF METABOLISM; INTELLECTUAL IMPAIRMENT; KARYOTYPING; MACROCEPHALY; MECP2 GENE; MEDICAL HOME; MICROARRAY ANALYSIS; MICROCEPHALY; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PEDIGREE ANALYSIS; PROTON NUCLEAR MAGNETIC RESONANCE; SEQUENCE ANALYSIS; WHOLE EXOME SEQUENCING; WHOLE GENOME SEQUENCING; X CHROMOSOME LINKED DISORDER; DISABILITY; FEMALE; GENETICS; MALE; METHODOLOGY; PSYCHOLOGICAL ASPECT; REVIEW;

DEVELOPMENTAL DISABILITIES; DISABILITY EVALUATION; FEMALE; HUMANS; INTELLECTUAL DISABILITY; KARYOTYPING; MALE;

EID: 84907199321     PISSN: 00314005     EISSN: 10984275     Source Type: Journal    
DOI: 10.1542/peds.2014-1839     Document Type: Article

References (91)

1. Moeschler JB, Shevell M; American Academy of Pediatrics Committee on Genetics. Clinical genetic evaluation of the child with mental retardation or developmental delays. Pediatrics. 2006;117(6):2304-2316
2. Johnson CP, Myers SM; American Academy of Pediatrics Council on Children With Disabilities. Identification and evaluation of children with autism spectrum disorders. Pediatrics. 2007;120(5):1183-1215
3. Lopez-Rangel E, Mickelson E, Lewis MES. The value of a genetic diagnosis for individuals with intellectual disabilities: optimising healthcare and function across the lifespan. Br J Dev Disabil. 2008;54(107 pt 2):69-82
4. Ronen GM, Fayed N, Rosenbaum PL. Outcomes in pediatric neurology: a review of conceptual issues and recommendations. The 2010 Ronnie Mac Keith Lecture. Dev Med Child Neurol. 2011;53(4):305-312
5. Rosenbaum PL. Prevention of psychosocial problems in children with chronic illness. CMAJ. 1988;139(4):293-295
6. Makela NL, Birch PH, Friedman JM, Marra C.A. Parental perceived value of a diagnosis for intellectual disability (ID): a qualitative comparison of families with and without a diagnosis for their child's ID. Am J Med Genet A. 2009;149A(11):2393-2402
7. Schalock RL, Luckasson RA, Shogren KA, et al. The renaming of mental retardation: understanding the change to the term intellectual disability. Intellect Dev Disabil. 2007;45(2):116-124
8. Moeschler JB, Nisbeft J. Invited comment on terminology. Am J Med Genet A. 2011; 155A(5):972-973
9. Centers for Disease Control and Prevention. Economic costs associated with mental retardation, cerebral palsy, hearing loss, and vision impairment-United States, 2003. MMWR Morb Mortal Wkly Rep. 2004;53(3):57-59
10. Shevell M, Ashwal S, Donley D, et al; Quality Standards Subcommittee of the American Academy of Neurology; Practice Committee of the Child Neurology Society. Practice parameter: evaluation of the child with global developmental delay: report of the Quality Standards Subcommittee of the American Academy of Neurology and The Practice Committee of the Child Neurology Society. Neurology. 2003;60(3):367-380
11. Schaefer GB, Bodensteiner JB. Evaluation of the child with idiopathic mental retardation. Pediatr Clin North Am. 1992;39(4):929-943
12. van Karnebeek CD, Jansweijer MC, Leenders AG, Offringa M, Hennekam RC. Diagnostic investigations in individuals with mental retardation: a systematic literature review of their usefulness. Eur J Hum Genet. 2005; 13(1):6-25
13. Van Karnebeek CS, Stockler IS. Evidencebased approach to identify treatable metabolic diseases causing intellectual disability. Paper presented at: Annual Conference of the American College of Medical Genetics; March 11, 2011; Vancouver, BC, Canada
14. Manning M, Hudgins L; Professional Practice and Guidelines Committee. Array-based technology and recommendations for utilization in medical genetics practice for detection of chromosomal abnormalities. Genet Med. 2010;12(11):742-745
15. Miller DT, Adam MP, Aradhya S, et al. Consensus statement: chromosomal microarray is a first-tier clinical diagnostic test for individuals with developmental disabilities or congenital anomalies. Am J Hum Genet. 2010;86(5):749-764
16. Coulter ME, Miller DT, Harris DJ, et al. Chromosomal microarray testing influences medical management. Genet Med. 2011; 13(9):770-776
17. Nowakowska B, Stankiewicz P, Obersztyn E, et al. Application of metaphase HR-CGH and targeted Chromosomal Microarray Analyses to genomic characterization of 116 patients with mental retardation and dysmorphic features. Am J Med Genet A. 2008; 146A(18):2361-2369
18. Pickering DL, Eudy JD, Olney AH, et al. Arraybased comparative genomic hybridization analysis of 1176 consecutive clinical genetics investigations. Genet Med. 2008;10 (4):262-266
19. Aradhya S, Manning MA, Splendore A, Cherry AM. Whole-genome array-CGH identifies novel contiguous gene deletions and duplications associated with developmental delay, mental retardation, and dysmorphic features. Am J Med Genet A. 2007;143A (13):1431-1441
20. Adam MP, Justice AN, Schelley S, Kwan A, Hudgins L, Martin CL. Clinical utility of array comparative genomic hybridization: uncovering tumor susceptibility in individuals with developmental delay. J Pediatr. 2009;154(1):143-146
21. Saul RA, Moeschler JB. How best to use CGH arrays in the clinical setting. Genet Med. 2009;11(5):371-, author reply 371-372
22. Bremer A, Giacobini M, Eriksson M, et al. Copy number variation characteristics in subpopulations of patients with autism spectrum disorders. Am J Med Genet B Neuropsychiatr Genet. 2011;156(2):115-124
23. Fan YS, Jayakar P, Zhu H, et al. Detection of pathogenic gene copy number variations in patients with mental retardation by genomewide oligonucleotide array comparative genomic hybridization. Hum Mutat. 2007;28(11):1124-1132
24. Bar-Shira A, Rosner G, Rosner S, Goldstein M, Orr-Urtreger A. Array-based comparative genome hybridization in clinical genetics. Pediatr Res. 2006;60(3):353-358
25. Vissers LE, de Vries BB, Veltman JA. Genomic microarrays in mental retardation: from copy number variation to gene, from research to diagnosis. J Med Genet. 2010; 47(5):289-297
26. Redon R, Ishikawa S, Fitch KR, et al. Global variation in copy number in the human genome. Nature. 2006;444(7118):444-454
27. Iafrate AJ, Feuk L, Rivera MN, et al. Detection of large-scale variation in the human genome. Nat Genet. 2004;36(9):949-951
28. Michelson DJ, Shevell MI, Sherr EH, Moeschler JB, Gropman AL, Ashwal S. Evidence report: Genetic and metabolic testing on children with global developmental delay: report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. Neurology. 2011;77(17):1629-1635
29. Taylor MR, Jirikowic J, Wells C, et al. High prevalence of array comparative genomic hybridization abnormalities in adults with unexplained intellectual disability. Genet Med. 2010;12(1):32-38
30. Whibley AC, Plagnol V, Tarpey PS, et al. Fine-scale survey of X chromosome copy number variants and indels underlying intellectual disability. Am J Hum Genet. 2010; 87(2):173-188
31. Hoyer J, Dreweke A, Becker C, et al. Molecular karyotyping in patients with mental retardation using 100K single-nucleotide polymorphism arrays. J Med Genet. 2007; 44(10):629-636
32. Lee C, Iafrate AJ, Brothman AR. Copy number variations and clinical cytogenetic diagnosis of constitutional disorders. Nat Genet. 2007;39(suppl 7):S48-S54
33. Van Naarden Braun K, Yeargin-Allsopp M. Epidemiology of intellectual disabilities. In: Levene MI, Chervenak FA, eds. Fetal and Neonatal Neurology and Neurosurgery. 4th ed . London: Elsevier; 2009:876-897
34. Tsuchiya KD, Shaffer LG, Aradhya S, et al. Variability in interpreting and reporting copy number changes detected by arraybased technology in clinical laboratories. Genet Med. 2009;11(12):866-873
35. Tucker T, Montpetit A, Chai D, et al. Comparison of genome-wide array genomic hybridization platforms for the detection of copy number variants in idiopathic mental retardation. BMC Med Genomics. 2011;4:25
36. Kaminsky EB, Kaul V, Paschall J, et al. An evidence-based approach to establish the functional and clinical significance of copy number variants in intellectual and developmental disabilities. Genet Med. 2011; 13(9):777-784
37. Lion-François L, Cheillan D, Pitelet G, et al. High frequency of creatine deficiency syndromes in patients with unexplained mental retardation. Neurology. 2006;67(9):1713-1714
38. Caldeira Araújo H, Smit W, Verhoeven NM, et al. Guanidinoacetate methyltransferase deficiency identified in adults and a child with mental retardation. Am J Med Genet A. 2005;133A(2):122-127
39. Engbers HM, Berger R, van Hasselt P, et al. Yield of additional metabolic studies in neurodevelopmental disorders. Ann Neurol. 2008;64(2):212-217
40. van Karnebeek CD, Scheper FY, Abeling NG, et al. Etiology of mental retardation in children referred to a tertiary care center: a prospective study. Am J Ment Retard. 2005;110(4):253-267
41. van Karnebeek CD, Stockler S. Treatable inborn errors of metabolism causing intellectual disability: a systematic literature review. Mol Genet Metab. 2012;105(3):368-381
42. Arias A, Corbella M, Fons C, et al. Creatine transporter deficiency: prevalence among patients with mental retardation and pitfalls in metabolite screening. Clin Biochem. 2007;40(16-17):1328-1331
43. Clark AJ, Rosenberg EH, Almeida LS, et al. X-linked creatine transporter (SLC6A8) mutations in about 1% of males with mental retardation of unknown etiology. Hum Genet. 2006;119(6):604-610
44. Yeargin-Allsopp M, Murphy CC, Cordero JF, Decouflé P, Hollowell JG. Reported biomedical causes and associated medical conditions for mental retardation among 10-year-old children, metropolitan Atlanta, 1985 to 1987. Dev Med Child Neurol. 1997;39 (3):142-149
45. Leonard H, Wen X. The epidemiology of mental retardation: challenges and opportunities in the new millennium. Ment Retard Dev Disabil Res Rev. 2002;8(3):117-134
46. Stevenson RE, Schwartz CE. X-linked intellectual disability: unique vulnerability of the male genome. Dev Disabil Res Rev. 2009;15(4):361-368
47. Raymond FL. X linked mental retardation: a clinical guide. J Med Genet. 2006;43(3): 193-200
48. Hersh JH, Saul RA; Committee on Genetics. Health supervision for children with fragile X syndrome. Pediatrics. 2011;127(5):994-1006
49. Stevenson RE, Schwartz CE. Clinical and molecular contributions to the understanding of X-linked mental retardation. Cytogenet Genome Res. 2002;99(1-4):265-275
50. Chiurazzi P, Schwartz CE, Gecz J, Neri G. XLMR genes: update 2007. Eur J Hum Genet. 2008;16(4):422-434
51. de Brouwer AP, Yntema HG, Kleefstra T, et al. Mutation frequencies of X-linked mental retardation genes in families from the EuroMRX consortium. Hum Mutat. 2007; 28(2):207-208
52. Tarpey PS, Smith R, Pleasance E, et al. A systematic, large-scale resequencing screen of X-chromosome coding exons in mental retardation. Nat Genet. 2009;41(5):535-543
53. Couvert P, Bienvenu T, Aquaviva C, et al. MECP2 is highly mutated in X-linked mental retardation. Hum Mol Genet. 2001;10(9): 941-946
54. Laccone F, Zoll B, Huppke P, Hanefeld F, Pepinski W, Trappe R. MECP2 gene nucleotide changes and their pathogenicity in males: proceed with caution. J Med Genet. 2002;39(8):586-588
55. Yntema HG, Kleefstra T, Oudakker AR, et al. Low frequency of MECP2 mutations in mentally retarded males. Eur J Hum Genet. 2002;10(8):487-490
56. Bourdon V, Philippe C, Martin D, Verloès A, Grandemenge A, Jonveaux P. MECP2 mutations or polymorphisms in mentally retarded boys: diagnostic implications. Mol Diagn. 2003;7(1):3-7
57. Kleefstra T, Yntema HG, Nillesen WM, et al. MECP2 analysis in mentally retarded patients: implications for routine DNA diagnostics. Eur J Hum Genet. 2004;12(1):24-28
58. dos Santos JM, Abdalla CB, Campos M, Jr, Santos-Rebouças CB, Pimentel MM. The A140V mutation in the MECP2 gene is not a common etiological factor among Brazilian mentally retarded males. Neurosci Lett. 2005;379(1):13-16
59. Ylisaukko-Oja T, Rehnström K, Vanhala R, et al. MECP2 mutation analysis in patients with mental retardation. Am J Med Genet A. 2005;132A(2):121-124
60. Donzel-Javouhey A, Thauvin-Robinet C, Cusin V, et al. A new cohort of MECP2 mutation screening in unexplained mental retardation: careful re-evaluation is the best indicator for molecular diagnosis. Am J Med Genet A. 2006;140(14):1603-1607
61. Tejada MI, Peñagarikano O, Rodriguez-Revenga L, et al. Screening for MECP2 mutations in Spanish patients with an unexplained mental retardation. Clin Genet. 2006;70(2):140-144
62. Campos M, Jr, Abdalla CB, Santos-Rebouças CB, et al. Low significance of MECP2 mutations as a cause of mental retardation in Brazilian males. Brain Dev. 2007;29(5):293-297
63. Schaefer GB, Bodensteiner JB. Radiological findings in developmental delay. Semin Pediatr Neurol. 1998;5(1):33-38
64. Moeschler JB, Bennett FC, Cromwell LD. Use of the CT scan in the medical evaluation of the mentally retarded child. J Pediatr. 1981; 98(1):63-65
65. Lingam S, Read S, Holland IM, Wilson J, Brett EM, Hoare RD. Value of computerised tomography in children with non-specific mental subnormally. Arch Dis Child. 1982; 57(5):381-383
66. Gabrielli O, Salvolini U, Coppa GV, et al. Magnetic resonance imaging in the malformative syndromes with mental retardation. Pediatr Radiol. 1990;21(1):16-19
67. Majnemer A, Shevell MI. Diagnostic yield of the neurologic assessment of the developmentally delayed child. J Pediatr. 1995;127(2):193-199
68. Shevell MI, Majnemer A, Rosenbaum P, Abrahamowicz M. Etiologic yield of subspecialists' evaluation of young children with global developmental delay. J Pediatr. 2000;136(5):593-598
69. Demaerel P, Kingsley DP, Kendall BE. Isolated neurodevelopmental delay in childhood: clinicoradiological correlation in 170 patients. Pediatr Radiol. 1993;23(1):29-33
70. Griffiths PD, Batty R, Warren D, et al The use of MR imaging and spectroscopy of the brain in children investigated for developmental delay: what is the most appropriate imaging strategy? Eur Radiol. 2011;21(9):1820-1830
71. Verbruggen KT, Meiners LC, Sijens PE, Lunsing RJ, van Spronsen FJ, Brouwer OF. Magnetic resonance imaging and proton magnetic resonance spectroscopy of the brain in the diagnostic evaluation of developmental delay. Eur J Paediatr Neurol. 2009;13(2):181-190
72. Kjos BO, Umansky R, Barkovich AJ. Brain MR imaging in children with developmental retardation of unknown cause: results in 76 cases. AJNR Am J Neuroradiol. 1990;11 (5):1035-1040
73. Bouhadiba Z, Dacher J, Monroc M, Vanhulle C, Ménard JF, Kalifa G. [MRI of the brain in the evaluation of children with developmental delay]. J Radiol. 2000;81(8):870-873
74. Hunter AG. Outcome of the routine assessment of patients with mental retardation in a genetics clinic. Am J Med Genet. 2000;90 (1):60-68
75. Harbord MG, Finn JP, Hall-Craggs MA, Robb SA, Kendall BE, Boyd SG. Myelination patterns on magnetic resonance of children with developmental delay. Dev Med Child Neurol. 1990;32(4):295-303
76. Strømme P. Aetiology in severe and mild mental retardation: a population-based study of Norwegian children. Dev Med Child Neurol. 2000;42(2):76-86
77. Martin E, Keller M, Ritter S, Largo RH, Thiel T, Loenneker T. Contribution of proton magnetic resonance spectroscopy to the evaluation of children with unexplained developmental delay. Pediatr Res. 2005;58(4):754-760
78. Wilder RT, Flick RP, Sprung J, et al. Early exposure to anesthesia and learning disabilities in a population-based birth cohort. Anesthesiology. 2009;110(4):796-804
79. Sprung J, Flick RP, Katusic SK, et al. Attentiondeficit/ hyperactivity disorder after early exposure to procedures requiring general anesthesia. Mayo Clin Proc. 2012;87(2):120-129
80. Turchi RM, Berhane Z, Bethell C, Pomponio A, Antonelli R, Minkovitz CS. Care coordination for CSHCN: associations with family-provider relations and family/child outcomes. Pediatrics. 2009;124(suppl 4):S428-S434
81. Shipman SA, Lan J, Chang CH, Goodman DC. Geographic maldistribution of primary care for children. Pediatrics. 2011;127(1):19-27
82. McGrath RJ, Laflamme DJ, Schwartz AP, Stransky M, Moeschler JB. Access to genetic counseling for children with autism, Down syndrome, and intellectual disabilities. Pediatrics. 2009;124(suppl 4):S443-S449
83. Hawkins AK, Hayden MR. A grand challenge: providing benefits of clinical genetics to those in need. Genet Med. 2011;13(3):197-200
84. Ledbetter DH. Cytogenetic technology-genotype and phenotype. N Engl J Med. 2008; 359(16):1728-1730
85. Cooley WC. Redefining primary pediatric care for children with special health care needs: the primary care medical home. Curr Opin Pediatr. 2004;16(6):689-692
86. Roach JC, Glusman G, Smit AF, et al. Analysis of genetic inheritance in a family quartet by whole-genome sequencing. Science. 2010;328(5978):636-639
87. Lupski JR, Reid JG, Gonzaga-Jauregui C, et al. Whole-genome sequencing in a patient with Charcot-Marie-Tooth neuropathy. N Engl J Med. 2010;362(13):1181-1191
88. Worthey EA, Mayer AN, Syverson GD, et al. Making a definitive diagnosis: successful clinical application of whole exome sequencing in a child with intractable inflammatory bowel disease. Genet Med. 2011;13(3):255-262
89. Bamshad MJ, Ng SB, Bigham AW, et al. Exome sequencing as a tool for Mendelian disease gene discovery. Nat Rev Genet. 2011;12(11):745-755
90. Jacob HJ. Next-generation sequencing for clinical diagnostics. N Engl J Med. 2013;369 (16):1557-1558
91. Yang Y, Muzny DM, Reid JG, et al. Clinical whole-exome sequencing for the diagnosis of Mendelian disorders. N Engl J Med. 2013; 369(16):1502-1511